Health Care Technology

Aclarion

Aclarion released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 57.25K, actual EPS USD -14.9969

Aclarion released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 18.94 K (forecast USD 20 K), actual EPS USD -2.9299 (forecast USD -2.64)

Aclarion Inc. Announces $2.5 Million Registered Direct Offering

Aclarion released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 19.32 K (forecast USD 30 K), actual EPS USD -2.7486 (forecast USD -2.26)

Aclarion released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 38.31 K, actual EPS USD -9.0924

Aclarion Registers First Patient for CLARITY Trial

Aclarion Uses AI Algorithms to Help Doctors Identify Chronic Hypoxemia

Aclarion to showcase NOCISCAN technology at Top Spine Innovation Forum

Aclarion released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 18.99 K (forecast USD 30 K), actual EPS USD -9.3183 (forecast USD -1.447 K)

Aclarion Announces Texas Back Institute's Participation in CLARITY Trial

Aclarion Inc Reaches Business Agreement with Louisiana Spinal Institute

Aclarion Inc Files Up to $150 Million Shelf Registration with SEC

Aclarion Releases Updated Investor Presentation for MicroCap Showcase

Aclarion Releases Cost-effectiveness Analysis of Nociscan Technology

Aclarion released FY2024 Q4 earnings on April 9 (EST), actual revenue USD 10.23 K (forecast USD 17.5 K), actual EPS USD 0 (forecast USD -1.131 K)

Aclarion released FY2024 annual earnings on April 9 (EST), actual revenue USD 45.72 K (forecast USD 55 K), actual EPS USD 0 (forecast USD -7.372 K)

Aclarion Inc Updates on Company Positioning Strength and Clarity Trial Funding Status

Aclarion Partners with RadNet to Expand Business, Covering 50 Imaging Centers Amid Economic Challenges

Aclarion Obtains US Patent to Expand Applications of Magnetic Resonance Spectroscopy in Pain and Infection Detection

Aclarion, Inc. Secures Nearly $20 Million Funding for CLARITY Trial

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Veeva Systems -CL

Doximity

Waystar

Phreesia

HealthStream

OptimizeRx

LifeMD

CareCloud

Forian

Certara

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap